These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29880050)

  • 1. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
    Wang T; Zhang T; Meng T; Li Y; Chen L; Yang Q; Dong H; Lei J; Chen L; Dong Y
    J Transl Med; 2018 Jun; 16(1):157. PubMed ID: 29880050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and efflux kinetics, and intracellular activity of voriconazole against Aspergillus fumigatus in human pulmonary epithelial cells: a new application for the prophylaxis and early treatment of invasive pulmonary aspergillosis.
    Wang T; Yang Q; Chen L; Li Y; Meng T; Wang Y; Zhang T; Lei J; Xing J; Dong Y
    Fundam Clin Pharmacol; 2017 Jun; 31(3):311-318. PubMed ID: 28012206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
    Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
    J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
    Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
    Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of the Orotomides against
    Hope WW; McEntee L; Livermore J; Whalley S; Johnson A; Farrington N; Kolamunnage-Dona R; Schwartz J; Kennedy A; Law D; Birch M; Rex JH
    mBio; 2017 Aug; 8(4):. PubMed ID: 28830945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
    Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
    Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
    Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
    J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.
    Huurneman LJ; Neely M; Veringa A; Docobo Pérez F; Ramos-Martin V; Tissing WJ; Alffenaar JW; Hope W
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2336-42. PubMed ID: 26833158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
    Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
    Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
    Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
    Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.
    Meletiadis J; Pournaras S; Roilides E; Walsh TJ
    Antimicrob Agents Chemother; 2010 Feb; 54(2):602-9. PubMed ID: 19995928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
    Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
    Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APX001 Pharmacokinetic/Pharmacodynamic Target Determination against
    Zhao M; Lepak AJ; Marchillo K; Vanhecker J; Sanchez H; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.
    Box H; Negri C; Livermore J; Whalley S; Johnson A; McEntee L; Alastruey-Izquierdo A; Meis JF; Thornton C; Hope W
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439967
    [No Abstract]   [Full Text] [Related]  

  • 20. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
    Lepak AJ; Marchillo K; Vanhecker J; Andes DR
    Antimicrob Agents Chemother; 2013 Jan; 57(1):579-85. PubMed ID: 23147740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.